6505--Lurasidone Tablets (VA-24-00084543)
ID: 36E79724R0022Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/07fa2d38f5db4cfc953c064b7bb79a14/view
Timeline
    Description

    The Department of Veterans Affairs is seeking proposals for the procurement of Lurasidone HCL tablets, aimed at establishing a reliable supply source for these pharmaceutical products to be distributed through the VA and Department of Defense's Pharmaceutical Prime Vendor Programs. The Request for Proposal (RFP) outlines specific requirements, including quantities for a base year and four option years, as well as detailed packaging, labeling, and compliance with the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP). This procurement is critical for ensuring consistent access to essential medications for veterans and military personnel. Interested offerors should contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further details and to submit proposals that include a 0.5% Cost Recovery Fee, adhering to the outlined guidelines and deadlines.

    Point(s) of Contact
    Ray RoldanContract Specialist
    Raymond.Roldan@va.gov
    Files
    Title
    Posted
    _rels/.rels
    [Content_Types].xml
    36E79724R0022_1.docx
    36E79724R0022.docx
    The document outlines a Request for Proposal (RFP) issued by the Department of Veterans Affairs for pharmaceutical products, specifically Lurasidone HCL tablets in various strengths. The objective is to establish a supply source for these drugs, primarily for distribution through the VA and Department of Defense's Pharmaceutical Prime Vendor Programs. It specifies required quantities for a base year and four option years, along with detailed packaging and labeling guidelines, including safety-cap requirements and barcoding as mandated by the Drug Supply Chain Security Act (DSCSA). Offerors must provide proposals that reflect pricing inclusive of a 0.5% Cost Recovery Fee, and must ensure FDA compliance with Good Manufacturing Practices (cGMP). The contract also emphasizes the need for written commitments from manufacturers if the offeror is a distributor and mandates a quarterly sales reporting structure. Additionally, it outlines the consequences of non-compliance and the process for addressing backorders, along with stipulations regarding covered drugs and program participants. This RFP indicates the VA's commitment to ensuring consistent access to essential medications while adhering to federal regulations and best practices in pharmaceutical distribution.
    36E79724R0022 0001.docx
    The government agency has issued an amendment to a solicitation for Lurasidone Tablets procurement. The original deadline for submitting offers was August 16, 2024, but this has been extended until August 26, 2024, at 2:30 PM CT. All other terms and conditions of the solicitation remain unchanged. Offerors must acknowledge receipt of this amendment by the extended deadline, using one of three specified methods, or risk their offers being rejected. This amendment is a routine administrative change to allow potential suppliers more time to prepare and submit their offers.
    docProps/app.xml
    docProps/core.xml
    word/_rels/document.xml.rels
    word/document.xml
    word/fontTable.xml
    word/settings.xml
    word/styles.xml
    word/theme/theme1.xml
    word/webSettings.xml
    Lifecycle
    Title
    Type
    6505--Lurasidone Tablets (VA-24-00084543)
    Currently viewing
    Solicitation
    6505--Lurasidone Tablets (VA-24-00084543)
    Presolicitation
    Similar Opportunities
    6505--CGRP Calcitonin Gene-Related Peptides
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for a contract to supply Calcitonin gene-related peptides (CGRP) as part of its Pharmaceutical Prime Vendor (PPV) Program. The procurement aims to establish a reliable source of these pharmaceutical products, ensuring compliance with federal regulations, including the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP). This initiative is crucial for maintaining consistent supply and quality control across VA medical facilities. Interested offerors must submit their proposals by October 31, 2024, at 2:30 PM CT, and can direct inquiries to Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used for treating high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties can contact Catherine Gilbert for more information. The solicitation is projected to be issued in December 2019.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Pramipexole Tablets, which are essential medications used primarily for the treatment of Parkinson's disease and restless legs syndrome. The procurement will include various dosages of Pramipexole (0.125 MG, 0.25 MG, 0.5 MG, 0.75 MG, 1 MG, and 1.5 MG) packaged in 90 count bottles, and the contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. This acquisition is unrestricted and fully competitive, aimed at establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should prepare for the solicitation, projected for October 2024, and may contact Ryan Guarnere at 215-737-2571 or Ryan.Guarnere@dla.mil for further inquiries.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Ketoconazole 2% Cream
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting bids for the supply of Ketoconazole 2% Cream, a pharmaceutical product essential for treating various skin conditions. Offerors are required to submit pricing for the base year and four option years, ensuring compliance with the Cost Recovery Fee of 0.5%, and must provide unique National Drug Codes (NDC) for their proposed products. This procurement aims to establish a reliable supply chain for pharmaceutical needs while adhering to federal procurement standards, emphasizing the importance of FDA cGMP compliance for manufacturers or authorized distributors. Interested parties should contact Contract Specialist Michael J Olszewski at Michael.Olszewski@va.gov for further details regarding the solicitation process.
    6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0027 770-25-1-8-1-0015 -National CMOP FENOFIBRATE
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified vendors to fulfill an emergency procurement of Fenofibrate pharmaceuticals, specifically 145 mg, under solicitation number 36C77025Q0027. The procurement involves delivering various quantities of the medication to multiple Consolidated Mail Outpatient Pharmacy (CMOP) locations, emphasizing compliance with federal regulations, including the Drug Supply Chain Security Act (DSCSA) and the Buy American Act. This initiative is crucial for ensuring timely access to essential pharmaceuticals for veterans, reflecting the VA's commitment to quality healthcare services. Interested vendors must submit their quotes, along with required documentation, by October 18, 2024, at 9:00 AM Central Time, with an anticipated award date of October 22, 2024. For further inquiries, vendors can contact Michael W. McAlhaney at Michael.McAlhaney@va.gov or (913) 684-0134.
    6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0028 770-25-1-801-0018 -National CMOP METFORMIN HCL
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking quotations for the emergency procurement of Metformin HCL 500mg 24HR SA Tablets, with a presolicitation notice issued under solicitation number 36C77025Q0028. The procurement involves multiple quantities of the medication to be delivered to various VA Consolidated Mail Outpatient Pharmacy (CMOP) locations across the United States, emphasizing the importance of timely and compliant pharmaceutical distribution to meet the needs of veterans. Interested vendors must submit their quotes, including a price schedule in Excel format, proof of state wholesale distributor licensure in compliance with the Drug Supply Chain Security Act, and other required documentation by October 21, 2024, at 09:00 AM CST, with an estimated award date of October 24, 2024. For further inquiries, vendors can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-0134.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.